CoChat

C9ORF72 Repeat Expansions in the Frontotemporal Dementias Spectrum of Diseases: A Flow-chart for Genetic Testing

Le Ber, Isabelle, the French research network on FTLD/FTLD-ALS, Camuzat, Agnès, Guillot-Noel, Lena, Hannequin, Didier, Lacomblez, Lucette, Golfier, Véronique, Puel, Michèle, Martinaud, Olivier, Deramecourt, Vincent, Rivaud-Pechoux, Sophie, Millecamps, Stéphanie, Vercelletto, Martine, Couratier, Philippe, Sellal, François, Pasquier, Florence, Salachas, François, Thomas-Antérion, Catherine, Didic, Mira, Pariente, Jérémie, Seilhean, Danielle, Ruberg, Merle, Wargon, Isabelle, Blanc, Frédéric, Camu, William, Michel, Bernard-François, Berger, Eric, Sauvée, Mathilde, Thauvin-Robinet, Christel, Mondon, Karl, Tournier-Lasserve, Elisabeth, Goizet, Cyril, Fleury, Marie, Viennet, Gabriel, Verpillat, Patrice, Meininger, Vincent, Duyckaerts, Charles, Dubois, Bruno, Brice, Alexis · 2013 · Journal of Alzheimer's Disease
Cited by 109

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Frontotemporal dementia (FTD) refers to a disease spectrum including the behavioral variant FTD (bvFTD), primary progressive aphasia (PPA), progressive supranuclear palsy/corticobasal degeneration syndrome (PSP/CBDS), and FTD with amyotrophic lateral sclerosis (FTD-ALS). A GGGGCC expansion in C9ORF72 is a major cause of FTD and ALS. C9ORF72 was analyzed in 833 bvFTD, FTD-ALS, PPA, and PSP/CBDS probands; 202 patients from 151 families carried an expansion. C9ORF72 expansions were much more frequent in the large subgroup of patients with familial FTD-ALS (65.9%) than in those with pure FTD (12.8%); they were even more frequent than in familial pure ALS, according to estimated frequencies in the literature (23-50%). The frequency of carriers in non-familial FTD-ALS (12.7%) indicates that C9ORF72 should be analyzed even when family history is negative. Mutations were detected in 6.8% of PPA patients, and in 3.2% of patients with a clinical phenotype of PSP, thus enlarging the phenotype spectrum of C9ORF72. Onset was later in C9ORF72 (57.4 years, 95%CI: 55.9-56.1) than in MAPT patients (46.8, 95%CI: 43.0-50.6; p = 0.00001) and the same as in PGRN patients (59.6 years; 95%CI: 57.6-61.7; p = 0.4). ALS was more frequent in C9ORF72 than in MAPT and PGRN patients; onset before age 50 and parkinsonism were indicative of MAPT mutations, whereas hallucinations were indicative of PGRN mutations; prioritization of genetic testing is thus possible. Penetrance was age- and gender-dependent: by age 50, 78% of male carriers were symptomatic, but only 52% of females. This can also guide genetic testing and counseling. A flowchart for genetic testing is thus proposed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-121456

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

Metadata

Authors
Le Ber, I., the French research network on FTLD/FTLD-ALS, Camuzat, A., Guillot-Noel, L., Hannequin, D., Lacomblez, L., Golfier, V., Puel, M., Martinaud, O., Deramecourt, V., Rivaud-Pechoux, S., Millecamps, S., Vercelletto, M., Couratier, P., Sellal, F., Pasquier, F., Salachas, F., Thomas-Antérion, C., Didic, M., Pariente, J., Seilhean, D., Ruberg, M., Wargon, I., Blanc, F., Camu, W., Michel, B.-F., Berger, E., Sauvée, M., Thauvin-Robinet, C., Mondon, K., Tournier-Lasserve, E., Goizet, C., Fleury, M., Viennet, G., Verpillat, P., Meininger, V., Duyckaerts, C., Dubois, B., & Brice, A.
Venue
Journal of Alzheimer's Disease
Published
2013-06-20
Volume
34
Issue
2
Pages
485-499
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W1581113100
Cited by
109
References
15
FWCI
9.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.